Rare diseases
Investigational molecules
Locations
44 Southampton Buildings, WC2A 1AP, United Kingdom
Clinical research is centered on refractory invasive pulmonary aspergillosis, with attention to treatment-resistant fungal infection affecting the lungs and the need for improved antifungal management in patients with limited response to standard care.
The sponsor’s research activity in this area reflects a focused interest in respiratory infectious disease and the clinical challenges associated with persistent Aspergillus infection.
Pulmocide Limited runs clinical trials in conditions such as Bronchopulmonary aspergillosis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
